Adequate Dosage of Sugammadex on Thyroid Surgery
- Conditions
- Thyroid Surgery
- Interventions
- Registration Number
- NCT03689413
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
This study was designed to compare two dosage of sugammadex after tracheal intubation for optimal condition of continuous intraoperative neuromonitoring in thyroid surgery to protect recurrent laryngeal nerve.
- Detailed Description
Vocal cord paralysis is not a rare complication in thyroid surgery. Nerve monitoring technique has been developed, and many clinicians use the technique for saving the concerned nerves. Many studies showed that the effect of sugammadex on reverse of neuromuscular blocking after tracheal intubation. However, optimal dosage was not founded for sugammadex.
This randomized controlled trial is to compare 1 mg/kg and 2 mg/kg as dosage of sugammadex for optimal continuous intraoperative neuromonitoring in thyroid surgery to prevent vocal cord paralysis.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 102
- The patients who need to open thyroid surgery
- Who doesn't agree to enroll
- Who has to receive other drug rather than rocuronium for muscle relaxant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 mg/kg Sugammadex 200 MG in 2 ML Injection For '2 mg/kg' group, sugammadex of 2 mg/kg (ex. 120 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation. We will use Sugammadex 200 MG in 2 ML Injection for this. 1 mg/kg Sugammadex 200 MG in 2 ML Injection For '1 mg/kg' group, sugammadex of 1 mg/kg (ex. 60 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation. We will use Sugammadex 200 MG in 2 ML Injection for this.
- Primary Outcome Measures
Name Time Method Quality of signal of neuromonitoring intraoperative During operation, surgeon evaluate the quality of signal of neuromonitoring on the basis of NIM III device.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Seoul Metropolitan Government Seoul National University Boramae Medical Center
🇰🇷Seoul, Korea, Republic of